DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Nifurtimox
Nifurtimox
Biopharmaceutical Optimization in Neglected Diseases for Paediatric Patients by Applying the Provisional Paediatric Biopharmaceu
Pharmacometabolomics of Meglumine Antimoniate in Patients with Cutaneous Leishmaniasis
Nifurtimox-Eflornithine Combination Therapy for Second-Stage
Adverse Events Associated with Nifurtimox Treatment for Chagas Disease in Children and Adults
Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
Newsletter No
Lampit) Reference Number: CP.PMN.256 Effective Date: 12.01.20 Last Review Date: 11.20 Line of Business: Commercial, HIM, Medicaid Revision Log
Drug-N-Therapeutics-Committee.Pdf
Chagas Disease Discovery (1909 – 2009)
Ending Neglected Tropical Diseases
World Health Organization Model List of Essential Medicines, 21St List, 2019
Pharmacological Approaches to Antitrypanosomal Chemotherapy
Antichagasic and Trichomonacidal Activity of 1-Substituted 2-Benzyl-5-Nitroindazolin-3-Ones and 3-Alkoxy-2-Benzyl-5-Nitro-2H-Ind
Efficacy and Toxicity of Fexinidazole and Nifurtimox Plus Eflornithine in the Treatment of African Trypanosomiasis: a Systematic Review
Advances and Challenges in the Treatment of Chagas Disease
Application for Inclusion of Fexinidazole in the Who Model List of Essential Medicines (Adult & Children)
Lack of Clinical Pharmacokinetic Studies to Optimize the Treatment of Neglected Tropical Diseases: a Systematic Review
Nifurtimox Versus Benznidazole Or Placebo for Asymptomatic Trypanosoma Cruzi Infection
Top View
Final1-Aritmo-Final-Report-V2-0Final.Pdf
Common Study Protocol for Observational Database Studies WP5 – Analytic Database Studies
Impact of Diseases
Leishmania Infantum Isolates Exhibit High Infectivity and Reduced Susceptibility to Amphotericin B
Leishmania Infantum Isolates Exhibit
The Selection and Use of Essential Medicines
Drugs for Parasitic Infections (2013 Edition)
Engineering Oral and Parenteral Amorphous Amphotericin B Formulations Against Experimental Trypanosoma Cruzi Infections
Acknowledgements Funding Transparency Declarations in Vitro
Identification of Trypanosoma Cruzi Growth Inhibitors with Activity In
In Vitro Benznidazole and Nifurtimox Susceptibility Profile of Trypanosoma Cruzi Strains Belonging to Discrete Typing Units
LAMPIT Safely and Effectively
Guidelines for Prevention and Treatment of Opportunistic
Monitoring the Use of Nifurtimox-Eflornithine Combination Therapy (NECT) in the Treatment of Second Stage Gambiense Human African Trypanosomiasis
Pharmacometabolomics of Meglumine Antimoniate in Patients with Cutaneous Leishmaniasis
Amebic Meningoencephalitis.Qxd
Biopharmaceutical Optimization in Neglected Diseases for Paediatric Patients by Applying the Provisional Paediatric Biopharmaceutical Classification System
And Body Weight-Adjusted Dosing in Patients with Chagas Disease
ATC-Index Mit DDD-Angaben Für Den Deutschen Arzneimittelmarkt Berlin 2013, 12
Informatics for Neglected Diseases Collaborations Frederic Bost*, Robert T Jacobs & Paul Kowalczyk
Australian Statistics on Medicines 2009
Essential Medicines WHO Model List (Revised March 2007) Explanatory Notes
Microorganisms-08-00950-V3.Pdf
Enterobius Vermicularis Infection1.Qxd
213464Orig1s000
Nifurtimox, Benznidazole, and Metronidazole
The Medical Letter
POM Analyses of Antitrypanosomal Activity of 2-Iminobenzimidazoles: Favorable and Unfavorable Parameters for Drugs Optimization
1 Supplementary Appendix Table of Contents Appendix
BENZNIDAZOLE TABLETS Safely and Effectively
Application Number
50 Years After Nifurtimox: Current and Future Chemotherapy for Chagas Disease
18Th Expert Committee on the Selection and Use of Essential Medicines Reviewer No
Toxic and Therapeutic Effects of Nifurtimox and Benznidazol on Trypanosoma Cruzi Ex Vivo Infection of Human Placental Chorionic
Study Protocol
Reviewer 2: NIFURTIMOX+EFLORNITHINE(N+E)
NECT Dossier
Lampit® (Nifurtimox) Fact Sheet
The Selection and Use of Essential Medicines
Facts & Figures
In Vitro Susceptibility of Trypanosoma Cruzi Strains from Santander, Colombia, to Hexadecylphosphocholine
A Multicentre, Randomised, Non-Inferiority Clinical Trial Comparing a Nifurtimox-Eflornithine Combination to Standard Eflornithi